ATLAS: A rationally designed anterograde transsynaptic tracer

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Neural circuits are fundamental to brain processing.
• Current retrograde tracing methods, like modified rabies virus, are effective but anterograde tracing lacks reliable, non-toxic tools.
• Understanding neural circuit connectivity is crucial for neuroscience research.

Purpose of the Study:

• To develop a novel, reliable, and non-toxic method for anterograde transsynaptic tracing of neural circuits.
• To enable precise mapping of neuronal connections in the forward direction.
• To provide a tool for activity-dependent circuit tracing.

Main Methods:

• Development of ATLAS (Anterograde Transsynaptic Label based on Antibody-like Sensors), utilizing an antibody-like protein (AMPA.FingR) targeting the AMPA receptor subunit GluA1.
• Engineering ATLAS to release AMPA.FingR and a payload (e.g., Cre recombinase) from presynaptic sites.
• Testing ATLAS in vivo and in dissociated cultures for efficacy, specificity, and toxicity.

Main Results:

• ATLAS successfully mediates strictly anterograde, synaptic, and non-toxic monosynaptic tracing from genetically defined cells.
• The method demonstrates activity dependence, suggesting potential for tracing circuits involved in specific behaviors.
• Successful application in both in vivo and in vitro model systems.

Conclusions:

• ATLAS provides a groundbreaking solution for anterograde neural circuit tracing, addressing a significant gap in neuroscience tools.
• The method's reliability, specificity, and non-toxicity make it a valuable asset for mapping brain connectivity.
• Activity-dependent tracing capabilities open new avenues for studying dynamic neural circuits and behavior.